For some companies, imitating the right rivals at the right time can be more effective—and lucrative—than attempting to chart an entirely new course. Sign up for HBR Executive Agenda - for insights ...

Mumbai: Sanofi India Limited has announced its financial results for the quarter ended June 30, 2025.The Company recorded a 9 ...

Funds should be able to invest more in promising local innovations, keeping IP in Australia and boosting productivity while ...

The pharmaceutical industry continues to evolve rapidly, driven by innovation, global health challenges, and technological ...

Foreign firms showed mixed reactions to the decision, with some willing to offload a 5% stake while others were not ...

The French pharmaceutical company claims that Sarclisa-VRD showed great improvement in the minimum residual disease (MRD) ...

Sanofi India Limited ( ($IN:SANOFI) ) has issued an update. Sanofi India Limited reported a 2% decline in net sales year-to-date but achieved a 6% ...

He said if they didn't, the US would deploy 'every tool in our arsenal' to protect families from 'continued abusive drug ...

FDA granted Orphan Drug Designation to Sanofi’s SAR446523, a monoclonal antibody targeting GPRC5D, for relapsed/refractory ...

BENGALURU] European stocks logged their biggest one-day drop in over three months on Friday (Aug 1), at the end of a busy ...

Experts are skeptical that Big Pharma companies will cut prices after President Donald Trump demands Most Favored Nation policies within 60 days.

U.S. sales of Eylea HD and Eylea, treatments for eye conditions like wet age-related macular degeneration, decrease 25% in ...